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Abstract
Background—Studies are published on settings adults receive influenza vaccination but few 
have reported on settings children are vaccinated and how this might be changing over time or 
vary by socio-demographics.
Methods—Data from the National Immunization Survey-Flu were analyzed to assess place of 
influenza vaccination among vaccinated children 6 months–17 years during the 2010–11, 2011–
12, 2012–13, and 2013–14 influenza seasons. The percentage of children vaccinated at each place 
was calculated overall and by age, race/ethnicity, income, and Metropolitan Statistical Area 
(MSA).
Results—The places children received influenza vaccination varied little over four recent 
influenza seasons. From the 2010–11 through 2013–14 influenza seasons the percentage of 
vaccinated children receiving influenza vaccination at a doctor’s office was 64.1%, 65.1%, 65.3%, 
and 65.3%, respectively with no differences from one season to the next. Likewise, for vaccination 
at clinics or health centers (17.8%, 17.5%, 17.0%. 18.0%), health departments (3.2%, 3.6%, 3.0%, 
2.8%), and other non-medical places (1.6%, 1.4%, 1.2%, 1.1%), there were no differences from 
one season to the next. There were some differences for vaccinations at hospitals, pharmacies, and 
schools. There was considerable variability in the place of influenza vaccination by age, race/
ethnicity, income, and MSA. Fewer Hispanic children were vaccinated at a doctor’s office than 
black, white, and other or multiple race children and fewer black children and children of other or 
multiple races were vaccinated at a doctor’s office than white children. More children at or below 
the poverty level were vaccinated at a clinic or health center than all of the other income groups.
Conclusion—Most vaccinated children receive their influenza vaccination at a doctor’s office. 
Place of vaccination changed little over four recent influenza seasons. Large variability in place of 
vaccination exists by age, race/ethnicity, income, and MSA. Monitoring place of vaccination can 
help shape future immunization programs.
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1. Introduction
Children have higher rates of influenza infection than adults and young children have higher 
rates of outpatient visits, hospitalizations, and deaths due to influenza compared to older 
children [1–3]. Influenza vaccination is the single best defense against influenza disease [4]. 
Beginning in 2004 all children 6–23 months were recommended to receive annual influenza 
vaccination [5]. In 2006 the influenza recommendations were expanded to include annual 
vaccination for all children 6–59 months [6]. Finally, the recommendations were further 
expanded in 2008 to include annual vaccination of all children 6 months through 18 years 
[7]. Since the 2010–11 influenza season, annual influenza vaccination has been 
recommended for all persons 6 months and older [8]. Influenza vaccination coverage with at 
least one dose among children is reported annually, with coverage among children 6 
months–17 years being 58.9% in the 2013–14 season [9]. This remains below the Healthy 
People target of 70% vaccination coverage [10].
Several studies have been published on the places where adults receive influenza vaccination 
[11–13]. However, few studies have reported on the settings where children receive 
influenza vaccinations and how this may be changing over time or vary by socio-
demographic characteristics [13]. In this descriptive study we report where children 6 
months through 17 years received influenza vaccination over four influenza seasons in the 
United States based on a large national survey. We also examine variation in place of 
vaccination by several socio-demographic characteristics. Knowing the places where 
children receive their influenza vaccination can aid in planning of influenza campaigns and 
can help with pandemic preparedness by providing information on where children routinely 
receive seasonal influenza vaccination.
2. Methods
Data from the National Immunization Survey-Flu (NIS-Flu), which began in the 2010–11 
influenza season, were analyzed to assess place of influenza vaccination among vaccinated 
children 6 months–17 years during the 2010–11, 2011–12, 2012–13, and 2013–14 influenza 
seasons. The NIS-Flu is a national list-assisted random-digit-dialed dual frame (land line and 
cellular telephone) survey of households with children. It includes three components: the 
NIS for children 19–35 months, the NIS-Teen for children 13–17 years, and the NIS-Child 
Influenza Module (NIS-CIM) for children 6–18 months and 3–12 years identified during the 
screening of households for the NIS and NIS-Teen. Data collection for NIS-Flu during the 
2010–11 season also included the National Survey of Children with Special Health Care 
Needs (NS-CSHCN), which used the same sampling frame as the NIS and identified 
children 6–18 months and/or 3–12 years for a short post-CSHCN influenza module. 
Interviews were conducted September through June for the 2010–11 and 2011–12 seasons 
and October through June for the 2012–13 and 2013–14 seasons. All 50 states and the 
District of Columbia were included in the survey. The Council of American Survey and 
Research Organizations (CASRO) [14] response rates for the NIS-Flu for the 2011–12 
through 2013–14 seasons ranged (over NIS-Flu component and season) from 51.8% to 
58.6% for the landline sample and 26.3–32.1% for the cellular telephone sample. The 
CASRO response rate range was wider for the 2010–11 season because of the NS-CSHCN, 
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and ranged from 38.1% to 73.6% for landline and 26.4% to 35.8% for cellular telephones. 
While estimates based on NIS and NIS-Teen typically rely on provider reported vaccination 
status, influenza vaccination status in the NIS-Flu is based only on parental report. Influenza 
vaccination coverage estimates from the NIS-Flu are posted annually on FluVaxView [9].
During the NIS-Flu survey, respondents were asked if their child had received an influenza 
vaccination and, if so, during which month and year. Children were considered vaccinated if 
they were reported to have received an influenza vaccination August through May for the 
2010–11 and 2011–12 season and July through May for the 2012–13 and 2013–14 seasons. 
National and state level influenza vaccination coverage estimates and methods were 
published previously; the estimates for children 6 months through 17 years were 51.0%, 
51.5%, 56.6%, and 58.9% respectively for the four influenza seasons [9]. For children who 
received an influenza vaccination, respondents were asked “At what kind of place did 
[selected child] get his/her most recent seasonal flu vaccination?” Responses were coded by 
the interviewer into the following categories which appeared on their computer screen 
during the interview: (1) doctor’s office, (2) health department, (3) clinic or health center, (4) 
hospital, (5) other medically-related place, (6) pharmacy or drug store, (7) workplace, (8) 
elementary/middle/high school, (9) other non-medically-related place, (10) don’t know, or 
(11) refused. Although some children in the study had received two doses of influenza 
vaccine in an influenza season, this study focused on place of the most recent dose received. 
Place of influenza vaccination was grouped into the following categories for analyses: (1) 
doctor’s office, (2) clinic or health center, (3) hospital or other medical place, (4) health 
department, (5) pharmacy, (6) school, (7) other non-medical place. The percentage of other 
medical place was very small (0.7%, 0.9%, 0.7%, and 0.6%, for the four influenza seasons 
respectively) and so was grouped along with hospital. The percentage of participants with 
don’t know or refused for place of influenza vaccination were 0.4%, 0.3%, 0.4%, and 0.5%, 
respectively for the four influenza seasons. Children for whom place of influenza 
vaccination was reported as don’t know or refused were excluded from study, i.e., they were 
not included in the denominator.
Information on the following socio-demographic characteristics were included in this study: 
child’s age as of November 1st, child’s race/ethnicity, income/poverty level, and 
Metropolitan Statistical Area (MSA) status. The income/poverty level variable was defined 
based on total family income in the past calendar year, and the U.S. Census poverty 
thresholds for that year specified for the applicable family size and number of children <18 
years. Poverty thresholds are available at http://www.census.gov/hhes/www/poverty/data/
threshld/index.html.
The NIS-Flu sample included a total of 116,799, 96,254, 100,829, and 126,860 children for 
the 2010–11, 2011–12, and 2012–13, 2013–14 seasons, respectively who were at least 6 
months as of November 1st of the respective influenza season and were not missing 
influenza vaccination status [9]. The analyses for this study was limited to subsets of this 
data (n = 44,736, n = 41,621, n = 51,826, and n = 67,843 for the four influenza seasons, 
respectively) that included children who had received at least one dose of influenza vaccine, 
and had information about place of influenza vaccination. For all four influenza seasons, we 
calculated the percentage of children receiving their most recent influenza vaccination at 
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each place. Additionally, these percentages were stratified by the socio-demographic 
variables. Differences between socio-demographic groupings in the percentages of children 
visiting a particular place for vaccination were tested using pair-wise comparison t-tests. 
Multivariable logistic regression analyses were used to determine variables independently 
associated with receipt of vaccination at each type of place. Adjusted prevalence ratios 
(APR) based on predicted marginals from the logistic regression models were computed 
[15]. A two-sided significance level of 0.05 was adopted for all statistical tests. Comparisons 
reported as being increases or decreases were statistically significant, while comparisons that 
were not statistically significant are reported as not being different. Reported percentages 
and corresponding 95% confidence intervals (95% CI) were weighted, while reported 
sample sizes were unweighted. All analyses were weighted to population totals and to adjust 
for households having multiple telephone lines, unit non-response, and non-coverage of non-
telephone households. Analyses were conducted using SAS release 9.3 (SAS Inc., Cary, NC) 
and SUDAAN release 11.0.0 (Research Triangle Institute, Research Triangle Park, NC) 
statistical software to take into account the complex survey design.
3. Results
Place of vaccination varied very little over the four influenza seasons studied. From the 
2010–11 through the 2013–14 influenza seasons the percentage of vaccinated children who 
received influenza vaccination at a doctor’s office was 64.1%, 65.1%, 65.3%, and 65.3%, 
respectively with no differences from one season to the next (Fig. 1). Likewise, for 
vaccination at clinics or health centers (17.8%, 17.5%, 17.0%. 18.0%), health departments 
(3.2%, 3.6%, 3.0%, 2.8%), and other non-medical places (1.6%, 1.4%, 1.2%, 1.1%), there 
were no differences from one season to the next. There was an increase in the percentage of 
children receiving vaccination at a hospital or other medical place from the 2010–11 season 
to the 2011–12 season (4.2–5.0%); however, from the 2012–13 to the 2013–14 season there 
was a similar decrease (4.9% to 4.2%). From the 2011–12 to the 2012–13 season there was 
an increase in the percentage of children receiving vaccinations at a pharmacy (2.9–3.8%). 
The percentage of children receiving influenza vaccination at schools decreased from the 
2010–11 season to the 2011–12 season (6.5–4.4%) and then did not change for subsequent 
seasons (Fig. 1).
There was considerable variability in the place of influenza vaccination by age, race/
ethnicity, income, and MSA (Table 1, Fig. 2). By age groups, the percentage of vaccinated 
children receiving vaccination at a doctor’s office decreased with increasing age for all four 
influenza seasons studied. During the 2013–14 season, this ranged from 76.7% for 6–23 
month olds down to 58.2% for 13–17 year olds (Table 1 and Fig. 2 [red bars]). The 
percentage receiving vaccination at a clinic or health center did not differ by age group for 
any season. The percentage receiving vaccination at a hospital or other medical place also 
did not differ by age group with the exception of the 2012–13 season in which more 6–23 
year olds than 5–12 year olds received vaccination at this type of place. The percentage 
receiving vaccination at a health department was lower for 6–23 month olds than the older 
age groups in all seasons except the 2010–11 season in which there were no age differences. 
The percentage of vaccinated children receiving vaccination at a pharmacy increased with 
increasing age for all four influenza seasons studied; however, the 6–23 year olds and the 2–
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4 year olds did not differ. In the 2013–14 season, the percentage ranged from 0.5% for 6–23 
year olds to 8.8% of 13–17 year olds (Table 1, Fig. 2). In all seasons studied, more of the 
vaccinated children 5–12 years and 13–17 years received vaccination in a school than 
younger children. Vaccination at an other non-medical place increased with increasing age 
(Table 1).
The examination of place of influenza by racial/ethnic groups showed that in all four seasons 
studied, among those vaccinated, a lower percentage of Hispanic children were vaccinated at 
a doctor’s office than black, white, and other or multiple race children. During the 2013–14 
season these percentages were 46.9%, 66.7%, 74.2%, and 65.4% respectively (Table 1 and 
Fig. 2 [blue bars]). In all four seasons studied, a lower percentage of black children and 
children of other or multiple races were vaccinated at a doctor’s office than white children. 
Conversely, in all four seasons, a higher percentage of Hispanic children were vaccinated at 
a clinic or health center than all other racial/ethnic groups, while a lower percentage of white 
children were vaccinated at this type of place. In the 2013–14 season, the percentages were 
37.2% Hispanic, 16.7% black, 9.0% white, and 15.8% other or multiple race. A lower 
percentage of white children than children of other race/ethnicity groups received influenza 
vaccination at a hospital or other medical place for all seasons studied. In the 2010–11 and 
2011–12 seasons, a lower percentage of Hispanic children than black children received 
vaccination at a health department, while in the 2012–13 and 2013–14 seasons there were no 
racial/ethnic group differences in receiving influenza vaccination at a health department. In 
all four seasons studied, a higher percentage of white children received influenza vaccination 
at a pharmacy than both Hispanic children and black children. There were no differences in 
any of the four seasons between Hispanic, black, and white children in the percentage 
receiving vaccination at school. The differences for other non-medical place are depicted in 
Table 1.
By income/poverty level, among those vaccinated, a lower percentage of vaccinated children 
at or below the poverty level were vaccinated at a doctor’s office than those of higher 
income or unknown income for all seasons studied (Table 1, Fig. 2 [green bars]). A higher 
percentage of children at or below the poverty level were vaccinated at a clinic or health 
center than all of the other income groups. A lower percentage of vaccinated children in 
households with income >$75K/year received vaccinations at a health department or a 
hospital or other medical place compared with the other income groups. A lower percentage 
of children at or below poverty received vaccination at a pharmacy compared with all other 
income groups for all seasons studied. Differences for other groups and places are denoted 
in Table 1.
By MSA status, a lower percentage of children in non-MSAs received vaccination at a 
doctor’s office than children residing in an MSA (Table 1, Fig. 2 [purple bars]). A lower 
percentage of children in MSA non-central city were vaccinated at a clinic or health center 
than children residing in an MSA central city or non-MSA. A higher percentage of children 
residing in a non-MSA received vaccination at a health department or school than those 
residing in an MSA.
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The results of the multivariable logistic regression analyses were not very different from the 
bivariate results, with most of the results remaining significant while controlling for other 
variables in the models (Table 2).
4. Discussion
This study provides national estimates of place of influenza vaccination for children over 
four influenza seasons. Almost two out of every three vaccinated children received influenza 
vaccination at a doctor’s office with the next most frequent setting being a clinic or health 
center, where nearly one in five vaccinated children received vaccination. All other settings 
for vaccination had a frequency of 5% or lower. There was stability over the four influenza 
seasons studied in the distribution of reported settings for influenza vaccination for children.
Comparing the estimates in this study to the places adults receive influenza vaccination 
showed marked differences. In the 2011–12 season 38.4% of vaccinated adults received 
vaccination at a doctor’s office and 8.4% at a clinic or health center, much lower than the 
percentage for children (65.1% and 17.5%, respectively) [12]. Adults were far more likely to 
be vaccinated at pharmacies than were children (adults: 20.1%; children: 2.9%) [12]. These 
results are not surprising because use of a medical home for vaccination of children has been 
encouraged as this helps to maintain continuity of care and increases the likelihood that 
other preventive health services will be delivered [16, 17]. Additionally, state laws vary on 
the minimum age for which pharmacists are permitted to administer influenza vaccination 
with many states allowing only the vaccination of adults [18]. However, vaccination 
provided in non-traditional settings, such as schools or pharmacies, can provide parents with 
more convenience and options for vaccinating their child [19, 20]. These settings can also 
play roles in increasing influenza vaccination coverage during routine influenza seasons and 
during influenza pandemics [19, 21].
Differences in estimates of place of influenza vaccination were observed by age, with older 
children more commonly vaccinated in non-medical settings relative to younger children. 
This is likely explained by a combination of factors including: the recommendation for 
young children to visit their health care provider frequently for well-child visits and to 
receive other vaccines recommended for young children; state pharmacy laws prohibiting 
vaccination of very young children; and availability of influenza vaccination at some schools 
for school-aged children [18]. Differences in place of influenza vaccination by MSA status 
revealed that schools and health departments play a larger role in delivering influenza 
vaccination in non-MSA areas than in MSA areas. This was not surprising given the larger 
distances between places in rural areas that may limit convenient access to medical facilities 
[22].
The differences in the distribution of settings for influenza vaccination by race/ethnicity and 
by income are less understood. Hispanic and black children (compared with white children) 
and children at or below poverty (compared with those above poverty) were much less 
commonly vaccinated at a doctor’s office while more commonly vaccinated at clinics or 
health centers. This might in part be attributable to racial/ethnic differences in vaccination-
seeking behavior; however, it is also likely due in part to barriers some parents have in 
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bringing their child to a doctor’s office during the influenza season such as lack of health 
insurance or a primary care doctor for the child, reduced ability to take off of work for a 
provider visit, and transportation issues. While pharmacies offer an option for some parents 
to have their child vaccinated, this appeared to be less so for children at or below poverty, 
who were vaccinated at pharmacies less frequently than other children. We speculate on 
these reasons but could not examine them with our available survey data.
This study is subject to at least five limitations. First, the NIS-Flu is a telephone survey with 
a moderate to low response rate especially for the cellular telephone sample, thus selection 
and non-response bias is possible and may remain even after weighting adjustments 
designed to reduce this bias. Second, estimates of place of influenza vaccination are based 
upon parental report and may be subject to some recall bias. Third, the survey question 
asked about place of the most recent influenza vaccination and some children in the study 
received more than one influenza dose. It is conceivable that some parents may take their 
child to different vaccination settings for their first versus second dose within the same 
influenza season; however, such a change in place within season is likely rare, but could not 
be evaluated with data available in this study. Fourth, some people’s interpretation of 
doctor’s office could include clinic, health center, or hospital; the categorization of 
vaccination setting for this study depended only on what the parent/guardian verbalized 
during the telephone survey. Lastly, we did not ask about reasons for choosing a particular 
setting for the child’s vaccination thus we could not assess whether where the children were 
vaccinated was driven by personal preference versus availability and access issues.
In conclusion, this study demonstrates that most vaccinated children receive their influenza 
vaccination at a doctor’s office, place of vaccination has changed very little over four 
influenza seasons, and large variability in place of vaccination exists by age, race/ethnicity, 
income, and MSA. Monitoring place of vaccination can help shape future immunization 
programs targeted at specific groups.
The findings and conclusions in this report are those of the authors and do not necessarily 
represent the views of the Centers for Disease Control and Prevention.
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Fig. 1. 
Reported place of influenza vaccination, children 6 months–17 years, United States, 
National Immunization Survey-Flu (NIS-Flu), 2010–11 through 2013–2014 influenza 
seasons.
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Fig. 2. 
Reported place of influenza vaccination by age*, race/ethnicty†, income/poverty‡, and MSA, 
children 6 months–17 years, United States, National Immunization Survey-Flu (NIS-Flu), 
2013–14 influenza season. (For interpretation of the references to color in the text, the reader 
is referred to the web version of the article.)
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is 
re
po
rte
d 
by
 re
sp
on
de
nt
; p
eo
pl
e 
of
 H
isp
an
ic
 e
th
ni
ci
ty
 m
ay
 b
e 
of
 a
ny
 ra
ce
.
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§ In
co
m
e/
po
v
er
ty
 w
as
 d
ef
in
ed
 b
as
ed
 o
n 
to
ta
l f
am
ily
 in
co
m
e 
in
 th
e 
pa
st 
ca
le
nd
ar
 y
ea
r, 
an
d 
th
e 
U
.S
. C
en
su
s p
ov
er
ty
 th
re
sh
ol
ds
 fo
r t
ha
t y
ea
r s
pe
ci
fie
d 
fo
r t
he
 a
pp
lic
ab
le
 fa
m
ily
 si
ze
 a
nd
 n
um
be
r o
f c
hi
ld
re
n 
<1
8 
ye
ar
s. 
Po
v
er
ty
 th
re
sh
ol
ds
 a
re
 av
ai
la
bl
e 
at
 h
ttp
://
w
w
w.
ce
n
su
s.
go
v
/h
he
s/w
w
w
/p
ov
er
ty
/d
at
a/
th
re
sh
ld
/in
de
x
.h
tm
l.
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